Latigo collects $150M to get non-opioid data to compete with Vertex in acute pain

Kyle LaHucik

Senior Reporter

Latigo Biotherapeutics thinks it can one-up Vertex Pharmaceuticals’ recently approved Journavx, which ignited the non-opioid landscape for treating pain.

The Los Angeles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Latigo collects $150M to get non-opioid data to compete with Vertex in acute pain

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

AstraZeneca to buy cell therapy startup for $425M upfront

AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancer

Lilly-backed UK biotech raises $72M to advance its antibody approach

HC Bioscience, a tRNA biotech backed by ARCH and Takeda, shuts down

Avidity seeks to 'set the standard' as it heads to FDA with Duchenne drug

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Lati­go col­lects $150M to get non-opi­oid da­ta to com­pete with Ver­tex in acute pain

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Latigo collects $150M to get non-opioid data to compete with Vertex in acute pain